Current treatments for acute myeloid leukemia (AML) are designed to target rapidly dividing blast populations with limited success in eradicating the functionally distinct leukemia stem cell (LSC) population, which is postulated to be responsible for disease resistance and relapse. We have previously reported high miR-126 expression levels to be associated with a LSC-gene expression profile. Therefore, we hypothesized that miR-126 contributes to ‘stemness’ and is a viable target for eliminating the LSC in AML. Here we first validate the clinical relevance of miR-126 expression in AML by showing that higher expression of this microRNA (miR) is associated with worse outcome in a large cohort of older (⩾60 years) cytogenetically normal AML patients treated with conventional chemotherapy. We then show that miR-126 overexpression characterizes AML LSC-enriched cell subpopulations and contributes to LSC long-term maintenance and self-renewal. Finally, we demonstrate the feasibility of therapeutic targeting of miR-126 in LSCs with novel targeting nanoparticles containing antagomiR-126 resulting in in vivo reduction of LSCs likely by depletion of the quiescent cell subpopulation. Our findings suggest that by targeting a single miR, that is, miR-126, it is possible to interfere with LSC activity, thereby opening potentially novel therapeutic approaches to treat AML patients.
Acute myeloid leukemia (AML) is a clonal, neoplastic disease that is heterogeneous at the molecular, cytogenetic, cellular and clinical levels.1, 2 Although advances have been made toward understanding the biology of AML, effective and relatively non-toxic treatments are still lacking and the prognosis is poor. The occurrence of multiple mutations and dysregulated gene expression contributes to the biological and clinical complexity of AML and impact on patients’ treatment response and overall prognosis.3 Furthermore, our view of a morphologically homogenous and functionally static blast population present in the bone marrow and blood of individual AML patients has now evolved into our current perspective of multiple dynamic and heterogeneous cell subpopulations including the relatively rare leukemia-initiating cells (that is, leukemia stem cells (LSCs)).4, 5 These cells have acquired abnormal self-renewal and partial maturation ability and are considered responsible for disease initiation and maintenance.6 Thus, targeting LSCs may represent an essential step for complete eradication of the disease. However, LSCs are resistant to conventional chemotherapy regimens, and novel approaches are needed to eliminate these cells and improve clinical outcome.7, 8
MicroRNAs (miRs) are small non-coding RNA molecules that regulate gene expression at the mRNA, DNA and/or protein level.9 miRs for the most part regulate mRNA expression by hybridizing to the 3′-untranslated region sequence of mRNAs, resulting in downregulation of target genes.9, 10 This mechanism has been shown to play an important regulatory role for both normal and malignant hematopoiesis,11, 12 and altered expression of miRs has been associated with clinical outcome in AML.3, 13, 14, 15, 16, 17
In normal hematopoiesis, miR-126 was found to be expressed in hematopoietic stem cells (HSCs) and early hematopoietic progenitor cells and to regulate HSC growth and activation.18 Furthermore, our group previously reported that high expression of miR-126 is associated with a LSC-enriched gene expression profile in cytogenetically normal (CN) AML.1 Altogether, these data support a role of miR-126 in myeloid leukemogenesis and suggest this miR as a potentially novel therapeutic target for AML LSCs.
We demonstrate that miR-126 knockdown decreased the number of LSCs by impairing stem cell self-renewal as determined by long-term colony-initiating cell (LTC-IC) and colony-forming cell (CFC) re-plating assays along with depletion of the quiescent cell sub-fraction. Efficient antagomiR-126 delivery using nanoparticles (NPs) conjugated to antibodies binding antigens present on LSCs, resulted in in vivo miR-126 knockdown and depletions of LSCs thereby leading to longer survival of leukemic mice in secondary transplant experiments. Altogether, these data support miR-126 as a novel therapeutic target to impact LSC activity in AML.
Materials and methods
Primary cells, miR-126 expression and methylation quantification
See Supplementary Methods for details.
RNA extraction, RNA expression quantification
Transferrin or anti-CD45.2 antibody-conjugated NP preparation
Previously, we developed a transferrin-targeted neutral NP delivery system.20 Briefly, positively charged polyethylenimine and negatively charged antagomiRs, anti-miR hsa-miR-126-3p (cat#AM17004; Ambion, Austin, TX, USA) or anti-miR-scramble (SCR; cat#AM17010; Ambion) form a polyplex core. This core was then loaded to pre-made anionic liposomal NPs to form lipopolyplex NPs. The formulation consisted of 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine, 1,2-dimyristoyl-sn-glycerol, methoxypolyethylene glycol and linoleic acid. Transferrin or anti-CD45.2 antibody conjugated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide(polyethylene glycol)-2000] (DSPE-PEG2000 maleimide) was then post-inserted to the surface of lipoplyplex NPs. The molar ratio of lipids to transferrin was 2000 as previous study20 and the molar ratio of lipids to anti-CD45.2 antibody was optimized to 10 000.
Flow cytometric analysis, sorting of HSCs, carboxyfluorescein succinimidyl ester (CFSE)-mediated tracking of cell division, cobblestone area-forming cell assays and colony-forming assays
In vivo studies
See Supplementary Methods for details.
For clinical correlative statistical analysis on miR-126 expression in primary patient samples, see Supplementary Methods.
For laboratory in vitro and in vivo experiments, two-tailed paired Student’s t-tests were performed using GraphPad Prism version 5.0a (GraphPad Software, Inc., La Jolla, CA, USA). P-values <0.05 were considered significant.
See Supplementary Methods for details.
Clinical relevance of miR-126 expression in AML
To determine miRs with biologic relevance to LSCs, we identified a miR expression profile associated with a LSC-specific gene expression signature1 in AML blasts. One of the most common miRs to be co-expressed with the LSC signature was miR-126. To determine if the variable levels of miR-126 observed in AML blasts had clinical significance, we analyzed miR-126 expression in CN-AML patients treated on Alliance/Cancer and Leukemia Group B cytarabine-anthracyclin-based protocols. miR-126 expression levels were higher in younger (<60 years) than older (⩾60 years) patients (Supplementary Figure 1A). However, miR-126 expression levels significantly impacted outcome only in older patients (Figure 1) and not in younger (Supplementary Figures 1B and D) patients. In older patients, higher miR-126 expression (treated as a continuous variable) was associated with lower complete remission (CR) rate (P=0.02) and shorter overall survival (OS; P=0.02) and event-free survival (EFS; P=0.02) duration (Table 1 and Figure 1a). The significant association of miR-126 levels with clinical (that is, higher white blood cells (WBCs)) and molecular features (that is, higher frequencies of wt NPM1 and TET2, mutated IDH2 and RUNX1 and higher expression of BAALC and MN1) at diagnosis suggested a complex interaction with other biologic events that may concurrently impact prognosis in chemotherapy-treated older CN-AML patients (Supplementary Table 1).
DNA hypermethylation of gene promoter regions is an epigenetic change frequently resulting in gene silencing. Epigenetic regulation of miR-126 expression by DNA methylation has been previously reported in normal and malignant cells.22 Thus, we also measured miR-126 promoter methylation in the same set of CN-AML patients by Methyl-Cap seq.23 We found a significantly inverse association between DNA methylation of the miR-126 promoter and miR-126 expression (P=0.001). Consistent with this association, we found that lower miR-126 promoter DNA methylation associated with higher miR-126 expression level and correlated with a worse CR rate (P=0.01) and shorter OS (P=0.003) and EFS (P=0.01) duration (see Table 1 and Figure 1b).
Patients with high miR-126 promoter DNA methylation and low miR-126 expression, determined, respectively, using median values of DNA methylation and expression levels as cutoffs, had a better outcome than the remaining patients (CR: P=0.08; OS: P=0.01; EFS: P=0.03; see Table 1 and Figure 1c).
Only the combined epigenetic/genetic status remained independently associated with outcome (that is, EFS; P=0.01) even after adjusting for other clinical and molecular predictors in a multivariable model (Table 2). Altogether, these results suggest that the miR-126 promoter methylation/expression combined variables seemingly predicted outcome better than miR-126 promoter methylation or expression separately, perhaps reflecting the complexity of miR-126 expression regulation through the combination of both epigenetic and signaling mechanisms.18
miR-126 expression in AML
In validating data using real-time PCR, we showed not only that variable levels of miR-126 expression levels occurred in primary AML blasts, but also that these levels are higher compared with normal bone marrow (BM) mononuclear cells (Figure 2a; see Supplementary Table 2 for patients’ molecular features). Previously, Lechman et al.18 showed a preferential expression and functional role for miR-126 in normal HSC and we demonstrated miR-126 expression to be correlated with the LSC-enriched gene expression signature,1 therefore we hypothesized a role for miR-126 in LSC functions in AML. Although in normal hematopoiesis HSCs are restricted to the immuno-phenotypically distinct CD34+CD38- compartment, it has been shown that in AML the stem cells can be found in both CD34+CD38- and CD34+CD38+ subpopulations.24 To determine which CD34/CD38 compartment was enriched in LTC-ICs in AML patients, we performed limiting dilution assays. CD34+CD38- and CD34+CD38+ subpopulations were first isolated by flow sorting and then serial dilutions of each of the two subpopulations were seeded onto irradiated stromal layers. After 6 weeks of culture, cobblestone area-forming cells were scored to determine the presence of LTC-ICs.21 The LTC-IC-enriched population varied within the CD34/CD38 subpopulations in different patient samples (Figure 2b). Higher miR-126 expression as determined by quantitative reverse transcription (RT)-PCR was found in the CD34/CD38 LTC-IC-enriched subpopulation for three of the four analyzed primary AML samples (Figure 2c). In the remaining patient (ptAML-1), no significant difference in miR-126 expression was found between CD34+CD38- and CD34+CD38+ populations. However, a relatively high number of LTC-ICs in both CD34+CD38- and CD34+CD38+ subpopulations was observed in this patient. Conversely, we found that less immature cells (that is, bulk and CD34-CD38+ blasts) had lower levels of miR-126 expression than CD34+CD38- and CD34+CD38+ blasts (see Supplementary Figure 2A). Furthermore, when we isolated the progeny of LTC-ICs after 6 weeks of culture, we found an increase in miR-126 expression within these cells compared with the CD34+ input cells from day 0 (see Supplementary Figure 2B). Together, these data suggest that increased miR-126 expression characterizes the LTC-IC-enriched CD34/CD38 sub-compartment and may help identify LSC-enriched cell subpopulations within AML patients’ samples.
Targeting miR-126 in primary human AML
Having shown the expression of miR-126 is higher in the LTC-IC-enriched cell subpopulations, we hypothesize a role for this miR in LSC self-renewal. To test our hypothesis, we sought to knockdown miR-126 in primary AML cells using Transferrin-conjugated anionic lipopolyplex NPs (Tf-NP) containing antagomiR-126. Recently, we showed that this NP-based formulation enables achievement of significant intracellular concentration of synthetic miRs or antagomiRs compared with free synthetic miR oligonucleotides in AML blasts expressing high levels of Tf receptor (CD71).20 As our data and others24 have reported LSCs to be present in both CD34+CD38- and CD34+CD38+ subpopulations (Figure 2b), we used CD34+ blasts sorted from primary AML patients for these experiments. CD34+ selected cells were treated for 24 h with Tf-NP-containing 200 nM of antagomiR-126 (anti-126) or antagomiR-scramble (SCR) and seeded for LTC-IC assays. After 6 weeks of co-culture on irradiated stromal layers, cobblestone area-forming cells were scored and LTC-IC frequency determined. Depending on the patient sample, Tf-NP-antagomiR-126-treated CD34+ cells had a 2.2- to 71.2-fold decrease in LTC-IC frequency compared with Tf-NP-antagomiR-SCR-treated controls (Figure 3a). Levels of miR-126 were ~80% decreased in Tf-NP-antagomiR-126-treated CD34+ blasts compared with Tf-NP-antagomiR-SCR-treated controls (P<0.01; Figure 3b). Importantly, we found no significant differences in apoptosis (Figure 3c) or proliferation (Figure 3d) rates over time in Tf-NP-antagomiR-126-treated CD34+ cells compared with Tf-NP-antagomiR-SCR-treated controls.
Tf-NP-antagomiR-126 and Tf-NP-antagomiR-SCR-treated CD34+ blasts were also used in CFU assays to assess the impact of miR-126 downregulation on LP activity. We found no significant differences in the number of CFC in primary Tf-NP-antagomiR-126-treated cells compared with Tf-NP-antagomiR-SCR-treated controls scored after 14 days in culture (Figure 3e). To determine if miR-126 knockdown impacted self-renewal capacity, we then harvested primary CFCs and re-plated them in methylcellulose for additional 14 days in culture. We found significant decreases in the number of CFU in the secondary colonies from Tf-NP-antagomiR-126-treated CD34+ blasts compared with Tf-NP-antagomiR-SCR-treated controls (Figure 3f). To determine how miR-126 knockdown impacts different cell states, we also assessed if any changes occurred within the quiescent cell subpopulation. AML blasts were stained with CFSE to allow for tracking of viable dividing cells and isolation of undivided CD34+ cells (CFSEmax/CD34+) after 6 days in liquid culture. Treatment of CD34+ AML blasts with Tf-NP-antagomiR-126 significantly reduced the absolute number of quiescent CFSEmax/CD34+ cells (P<0.05, Figure 3g), which, previously have been reported to be responsible for leukemia re-initiating ability.25, 26 Altogether, these results support a role for miR-126 in leukemic cell self-renewal. The miR downregulation could lead to unrestrained partial maturation into LP and decrease the quiescent LSC subpopulation while having little effect on survival of proliferating cells.
Targeting miR-126 in vivo
As in vitro targeting of miR-126 in CD34+ cells resulted in reduced LTC-IC frequency and the number of quiescent CFSEmax/CD34+ cells, next we sought to determine whether NP delivering antagomiR-126 could effectively target LSCs in vivo. Briefly, busulfan-conditioned NSG mice were engrafted with human AML primary blasts from patient ptAML-1 (Figure 4a). Eight weeks post primary transplant, mice were treated with Tf-NP-anti-SCR or Tf-NP-anti-126 (n=3 mice per group). Forty-eight hours after the last LNP treatment, BM cells were harvested and transplanted into busulfan-conditioned NSG secondary recipients using two different cell doses (2 × 106 and 5 × 104; n=5 mice per cell dose). We found that mice transplanted with the cells from Tf-NP-antagomiR-126-treated primary human-engrafted mice lived significantly longer than those transplanted with cells from the Tf-NP-antagomiR-SCR-treated primary human-engrafted mice (P<0.05 for both dose levels; Figure 4b).
Similar results were obtained using our previously established MllPTD/WT Flt3ITD/ITD double knock-in (dKI) mouse model, which develops an aggressive AML in primary mice, but also leads to death within 6 weeks in secondary BM transplantation (BMT) experiments. The MllPTD/WT Flt3ITD/ITD leukemic mouse model has been shown to recapitulate important clinical, cytogenetic and molecular features of the human disease.27 Similar to the human samples, miR-126 was also found to be increased within the BM Lin-Sca-1+c-kit+ (LSK) compartment, compared with the more mature Lin-Sca-1-c-kit+ (KL) compartment (Supplementary Figure 3). Using this mouse model allowed us to further characterize the phenotypic consequences of miR-126 knockdown in vivo.
We transplanted BM cells from primary dKI AML (CD45.2+) mixed with BM from wild-type (WT)-BoyJ (CD45.1+) donors into lethally irradiated WT-BoyJ (CD45.1+) recipients. As dKI leukemia cells do not express the Tf receptor on their cell surface, we used NPs conjugated to CD45.2 antibody, expressed exclusively on the donor (MllPTD/WT Flt3ITD/ITD) AML cells to target miR-126 specifically in the leukemia cells. Five weeks post BMT, mice were treated once daily for 5 consecutive days with anti-CD45.2-NP-antagomiR-126 or anti-CD45.2-NP-antagomiR-SCR control (see Materials and methods for NP administration). Forty-eight hours after the last dose, BM was harvested from the treated mice (Figure 5a). We confirmed successful targeting of miR-126 in vivo, by demonstrating ~50% decrease in miR-126 expression in BM and spleen from mice treated with anti-CD45.2-NP-antagomiR-126 compared with controls treated with anti-CD45.2-NP-antagomiR-SCR (Figure 5b). The functional consequences of miR-126 downregulation were assessed by testing the expression of three miR-126 putative targets that have been reported to have a role in cancer: MMP7, a matrix metalloproteinase and known miR-126 target gene;28 CHD7, an epigenetic regulator and possible negative regulator of HSC,29 and JAG1, a Notch ligand, important for normal hematopoiesis30 (Figure 5c). The expression levels of all three of these putative miR-126 target genes were found significantly increased in the BM cells from anti-CD45.2-antagomiR-126 vs anti-CD45.2-antagomiR-SCR-treated primary recipient mice (Figure 5c). Similar results were observed at the protein level (Supplementary Figure 4). No differences in disease burden or bulk blast viability were noted between the harvests from anti-CD45.2-NP-antagomiR-126 vs anti-CD45.2-NP-antagomiR-SCR-treated mice (Supplementary Figures 5A and B).
To analyze the impact of miR-126 downregulation on leukemia cell self-renewal activity in vivo, we performed secondary transplants using two different cell doses (105 and 106) of donor BM cells from MllPTD/WT Flt3ITD/ITD leukemic mice treated with anti-CD45.2-NP-antagomiR-126 or anti-CD45.2-NP-antagomiR-SCR along with 5.0 × 105 whole bone marrow (WBM) from WT-BoyJ (CD45.1) mice (Figure 5a). We found significant decreases in the levels of miR-126 in the BM and spleen of anti-CD45.2-NP-antagomiR-126-treated mice compared with anti-CD45.2-NP-antagomiR-SCR controls at the time of harvest (Figure 5b). Interestingly, at this early time point, we found no difference in the frequency of LSK or proliferating cells in the anti-CD45.2-NP-antagomiR-126 BM, suggesting that the difference in miR-126 levels was due to a knockdown of the miR expression rather than to a reduction of LSCs/AML cells (Supplementary Figures 5C and D).
To confirm that anti-CD45.2-NP-antagomiR-126 treatment resulted from a decrease in the number of LSCs resulting in prolonged survival of secondary recipients, we performed LTC-IC assays with BM cells from primary recipients treated with anti-CD45.2-NP-antagomiR-126 or anti-CD45.2-NP-antagomiR-SCR. We found a significant decrease in the frequency of LTC-ICs in BM cells harvested from anti-CD45.2-NP-antagomiR-126 compared with anti-CD45.2-NP-antagomiR-SCR-treated primary recipient mice (P<0.001; Figure 5d). Interestingly, when cells from anti-CD45.2-NP-antagomiR-126- or anti-CD45.2-NP-antagomiR-SCR-treated primary recipients were used in CFU assays we found that although the colonies were smaller, that there was an increase in the number of CFCs in the primary plating indicating that miR-126 knockdown had no initial, detrimental effect on LPs. However, when these cells were re-plated to assess leukemic cell self-renewal capacity, miR-126 knockdown resulted in a profound decrease in the ability to form colonies in secondary, tertiary and quaternary re-plating experiments (Figure 5e). These data from in vivo treated AML mice are consistent with those obtained with ex-vivo treated primary human CD34+ blasts (Figure 3) and indicate the partial exhaustive effect of miR-126 downregulation on LSC.
At a relatively early time point (2 weeks) post BMT, we found a significant decrease in the level of engraftment measured by percentage of chimerism in secondary recipients transplanted with BM cells from anti-CD45.2-NP-antagomiR-126-treated mice compared with recipients transplanted with BM from anti-CD45.2-NP-antimiR-SCR-treated primary recipient mice (Figure 5f; P<0.01). Following these mice longitudinally, we showed that mice transplanted with 106 and 105 cells from anti-CD45.2-NP-antagomiR-126-treated primary recipients had, respectively, a median survival of 46 and 60 days compared with 31 and 35 days of those transplanted with cells from the anti-CD45.2-NP-antagomiR-SCR-treated primary recipients (Figure 5g, P<0.01 for both cell doses). We performed full pathological analyses of BM or blood from both anti-CD45.2-NP-antagomiR-SCR- and anti-CD45.2-NP-antagomiR-126-treated mice, and found no differences in cellular morphology or expression of lineage markers (CD11b, Gr-1, Ter119, CD3 and B220; data not shown). These data demonstrate that in vivo knockdown of miR-126 leads to a decrease in functional LSCs.
Although a full toxicology assessment needs to be conducted, we have found no impact of the anti-CD45.2-NP-antagomiR-126 on normal hematopoiesis. When normal CD45.2 C57BL/6J mice were treated with anti-CD45.2-NP-antagomiR-126 or anti-CD45.2-NP-antagomiR-SCR, no statistically significant differences in WBC, BM and spleen cell numbers, or colony-forming ability were seen in mice treated with anti-CD45.2-NP-antagomiR-126 compared with anti-CD45.2-NP-antagomiR-SCR controls (Figures 6a and c). Furthermore, when we mixed BM from anti-CD45.2-NP-antagomiR-126 or anti-CD45.2-NP-antagomiR-SCR with C57BL/6J-CD45.1 (BoyJ) whole BM at a 1:1 ratio and transplanted into lethally irradiated syngeneic recipient mice (BoyJ), we found no significant differences in hematopoietic reconstitution from CD45.2 cells from the NP-containing antagomiR-126-treated mice compared with antagomiR-SCR controls (Figure 6d).
In AML, LSCs are defined as malignant cells that have acquired stem cell properties such as unlimited self-renewal, quiescence and long-term engraftment/sustained disease maintenance. Because of these acquired features, LSCs constitute a subpopulation of transformed hematopoietic cells capable of recapitulating disease in secondary transplantation experiments, the gold standard functional assay to verify LSC activity.24, 31 In addition to coding genes recently we, and others, have demonstrated a leukemogenic and prognostic role for miRs in AML.14, 15, 16, 17 Furthermore, we showed previously that increased miR-126 level is associated with enrichment of LSC gene expression in primary patient blasts1 and more recently that miR-126 has been shown to play a role in regulating normal HSC.32 Here, we report that variable expression of miR-126 occurs in both younger and older CN-AML patients, albeit differently from what reported by de Leeuw et al,32 we observed the clinical impact is age-related as only the older cohort was significantly affected. This may support age-related differences in disease etiology of distinct age groups. Interestingly, the miR-126 promoter methylation/expression combined variable is a seemingly better predictor of outcome than miR-126 promoter methylation or expression alone, thereby reflecting the complexity of miR-126 expression regulation through the combination of both by epigenetic and signaling mechanisms.18 This suggests that the altered epigenetic activation of miR-126 expression in leukemia may also lead to concomitant expression of other cancer-related genes/miRs via the same epigenetic mechanism, resulting in a more aggressive and therapy-resistant disease phenotype. Altogether, these results led us to hypothesize that targeting miR-126 expression may affect LSC activity and confer a therapeutic benefit in older AML patients. We tested this hypothesis by synthesizing a miR-126 antagomiR formulated in targeting (antigen- or antibody-conjugated) NPs.20 This approach enabled us not only to gain biologic insight into the role of miR-126 in AML LSCs, but also to lay the foundation for a future miR-based therapeutic approach for targeting this minute, but biologically and clinically relevant, subpopulation of leukemia cells.
Lechman et al.18 reported miR-126 to be important for the regulation of normal HSC and hematopoietic progenitor cells, and demonstrated potentially different functions for miR-126 in these cell compartments. Using lentiviral knockdown ‘sponge’ vectors to inhibit miR-126 function, they found that miR-126 knockdown resulted in an increase in HSC proliferation without exhaustion. In vivo they noted a long-term reduced hematopoietic activity supported by decreased output of myeloid and B cells. In contrast, when miR-126 was overexpressed in normal HSC (CD34+CD38-CD90+), the number of quiescent cells increased.18 Therefore, miR-126 seemingly has a regulatory role in hematopoiesis by balancing HSC proliferative/differentiation activities. As increased miR-126 in normal HSCs resulted in increased numbers of quiescent cells, we hypothesized that miR-126 may also have a pivotal role in AML by regulating the fractions of LSCs that remain quiescent and those that proliferate. Therefore, decreased miR-126 may deplete the reservoir of quiescent LSCs and reduce leukemia growth. This hypothesis was supported by our results showing decreases in the number of quiescent CFSEmax/CD34+ leukemia cells after in vitro treatment with antagomiR-126 and the longer survival observed in mice subjected to secondary transplant with marrow cells from antagomiR-126-treated primary leukemic donors.
The biology of LSCs has been shown to be distinct from that of the bulk blasts genetically, epigenetically and functionally. Although LSCs only comprise a very small population within AML, they most likely have a profound impact on the clinical presentation and biology of the disease and need to be eradicated in order to achieve cure in AML patients. However, efficient therapeutic targeting of the small LSC subpopulation in vivo has been challenging. We now show this limitation may be overcome by using antagomiR-126 delivery via novel specific antigen (Tf)- or antibody (anti-CD45.2)-conjugated anionic lipopolyplex NPs. As we previously reported, the chemical and physical characteristics of this formulation allow for bypassing hepatic uptake and ultimately a better delivery of the NP compound to hematopoietic organs without any evidence of toxicity.20 In our studies, we showed that NP delivery of antagomiR-126 can be achieved in rare AML subpopulations such as LSCs in vivo, and was not toxic to normal hematopoietic functions, as normal BM treated with anti-CD45.2-NP-antagomiR-126 showed no hematopoietic deficits. The activity of the NP-antagomiR-126 seems quite rapid, suggesting that even a relatively brief perturbation of miR-126 expression may permanently impact LSC function and lay the basis for potentially new therapeutic approaches. Importantly, although the antagomiR-126 was not modified with any fluorescent reporter to allow for a direct quantifiable assessment of oligo uptake in vivo, we are confident that robust intracellular oligos’ (antagomiR-126 and antagomiR-SCR) concentrations were sufficient that after only a few doses of NPs, we were able to demonstrate significant knockdown of miR-126 in vivo, increase the expression of miR-126 target genes and decrease LSC frequency in BM from anti-126-treated mice compared with anti-SCR-treated controls. This resulted in a delay of disease development and increased survival of leukemic mice in secondary transplants performed with equal numbers of viable mononuclear BM cells from anti-126-treated and anti-SCR-treated primary donor cells. Although the brief treatment with NP-antagomiR-126 had little impact on disease burden in the primary mice, as the percent of human primary cells in the BM of anti-126-treated mice was not significantly different than the anti-SCR-treated mice, 91.5±2.8% vs 90.7±2.6%, respectively (NS, n=3 mice per group). We were able to achieve a significant impact on survival in secondary recipients. These data suggest that the effect of antagomiR-126 may be most beneficial in residual LSC-enriched population cells similar to those that persist after treatment and likely drive disease relapse in chemotherapy-treated patients. Thus, it is reasonable to envision that combination of miR-126 inhibition and cytoreductive chemotherapy to target both proliferative 'bulk' blasts and LSCs may be a compelling strategy to eradicate the disease and prevent leukemia relapse in AML patients. Of course, delivery of antimiR-based therapeutics may need to be further refined for use in humans by optimizing NP packaging or considering emerging alternative formulations.33
In conclusion, we report the biological and preclinical relevance of targeting miR-126 in AML. We demonstrate the feasibility of miR-126 knockdown in vivo, interfering with LSC self-renewal utilizing a novel, cutting-edge antibody-conjugated NP approach. Recently, in vivo targeting of miR-196b was also reported to successfully eradicate LSCs. However, the relevance of this miR was seemingly limited to AML blasts harboring mixed-lineage leukemia translocations,34 whereas miR-126 has been found highly expressed in two of the most frequent cytogenetic subtypes of AML, that is, CN1 and core-binding factor,32 which together represent ~60% of all the AML cases. Therefore, the therapeutic targeting of miR-126 using NP-antagomiR-126 is potentially applicable to a broader group of AML patients. Although the therapeutic development of NP-antagomiR-126 is beyond the scope of the present work and precise pharmacokinetic/pharmacodynamics modeling to define the optimal dose and schedule of NP-antagomiR-126 to be used in vivo is needed, it seems reasonable to predict that combinations of NP-antagomiR-126 with cell cycle-dependent chemotherapeutics may be needed to completely eradiate the disease to achieve both effective cytoreduction of bulk blasts and cycling LPs, and LSC elimination, thus resulting in complete eradication of the disease.
Metzeler KH, Maharry K, Kohlschmidt J, Volinia S, Mrozek K, Becker H et al. A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia. Leukemia 2013; 27: 2023–2031.
Mawad R, Estey EH . Acute myeloid leukemia with normal cytogenetics. Curr Oncol Rep 2012; 14: 359–368.
Marcucci G, Mrozek K, Radmacher MD, Garzon R, Bloomfield CD . The prognostic and functional role of microRNAs in acute myeloid leukemia. Blood 2011; 117: 1121–1129.
Sagar J, Chaib B, Sales K, Winslet M, Seifalian A . Role of stem cells in cancer therapy and cancer stem cells: a review. Cancer Cell Int 2007; 7: 9.
Sarry JE, Murphy K, Perry R, Sanchez PV, Secreto A, Keefer C et al. Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rgammac-deficient mice. J Clin Invest 2011; 121: 384–395.
Heidel FH, Mar BG, Armstrong SA . Self-renewal related signaling in myeloid leukemia stem cells. Int J Hematol 2011; 94: 109–117.
Misaghian N, Ligresti G, Steelman LS, Bertrand FE, Basecke J, Libra M et al. Targeting the leukemic stem cell: the Holy Grail of leukemia therapy. Leukemia 2009; 23: 25–42.
Guzman ML, Rossi RM, Neelakantan S, Li X, Corbett CA, Hassane DC et al. An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood 2007; 110: 4427–4435.
Macfarlane LA, Murphy PR . MicroRNA: biogenesis, function and role in cancer. Curr Genomics 2010; 11: 537–561.
Garzon R, Marcucci G, Croce CM . Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 2010; 9: 775–789.
Havelange V, Garzon R, Croce CM . MicroRNAs: new players in acute myeloid leukaemia. Br J Cancer 2009; 101: 743–748.
Havelange V, Garzon R . MicroRNAs: emerging key regulators of hematopoiesis. Am J Hematol 2010; 85: 935–942.
Marcucci G, Radmacher MD, Mrozek K, Bloomfield CD . MicroRNA expression in acute myeloid leukemia. Curr Hematol Malignancy Rep 2009; 4: 83–88.
Marcucci G, Radmacher MD, Maharry K, Mrozek K, Ruppert AS, Paschka P et al. MicroRNA expression in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 358: 1919–1928.
Marcucci G, Mrozek K, Radmacher MD, Bloomfield CD, Croce CM . MicroRNA expression profiling in acute myeloid and chronic lymphocytic leukaemias. Best Practice Res Clin Haematol 2009; 22: 239–248.
Marcucci G, Maharry KS, Metzeler KH, Volinia S, Wu YZ, Mrozek K et al. Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients. J Clin Oncol 2013; 31: 2086–2093.
Garzon R, Volinia S, Liu CG, Fernandez-Cymering C, Palumbo T, Pichiorri F et al. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood 2008; 111: 3183–3189.
Lechman ER, Gentner B, van Galen P, Giustacchini A, Saini M, Boccalatte FE et al. Attenuation of miR-126 activity expands HSC in vivo without exhaustion. Cell Stem Cell 2012; 11: 799–811.
Alachkar H, Santhanam R, Maharry K, Metzeler KH, Huang X, Kohlschmidt J et al. SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome. J Clin Invest 2014; 124: 1512–1524.
Huang X, Schwind S, Yu B, Santhanam R, Wang H, Hoellerbauer P et al. Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia. Clin Cancer Res 2013; 19: 2355–2367.
Neviani P, Harb JG, Oaks JJ, Santhanam R, Walker CJ, Ellis JJ et al. PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. J Clin Invest 2013; 123: 4144–4157.
Li Z, Lu J, Sun M, Mi S, Zhang H, Luo RT et al. Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci USA 2008; 105: 15535–15540.
Marcucci G, Yan P, Maharry K, Frankhouser D, Nicolet D, Metzeler KH et al. Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score. J Clin Oncol 2013; 32: 548–556.
Eppert K, Takenaka K, Lechman ER, Waldron L, Nilsson B, van Galen P et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med 2011; 17: 1086–1093.
Samudio I, Harmancey R, Fiegl M, Kantarjian H, Konopleva M, Korchin B et al. Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. J Clin Invest 2010; 120: 142–156.
Guan Y, Gerhard B, Hogge DE . Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML). Blood 2003; 101: 3142–3149.
Zorko NA, Bernot KM, Whitman SP, Siebenaler RF, Ahmed EH, Marcucci GG et al. Mll partial tandem duplication and Flt3 internal tandem duplication in a double knock-in mouse recapitulates features of counterpart human acute myeloid leukemias. Blood 2012; 120: 1130–1136.
Felli N, Felicetti F, Lustri AM, Errico MC, Bottero L, Cannistraci A et al. miR-126&126* restored expressions play a tumor suppressor role by directly regulating ADAM9 and MMP7 in melanoma. PLoS ONE 2013; 8: e56824.
huang HT, Lee CT, Yu S, Zon LI, Speck NA . Chromatin remodeling enzyme CHD7 negatively regulate hematopoietic stem cell function. Blood 2013; 112: 2413.
Poulos MG, Guo P, Kofler NM, Pinho S, Gutkin MC, Tikhonova A et al. Endothelial Jagged-1 is necessary for homeostatic and regenerative hematopoiesis. Cell Rep 2013; 4: 1022–1034.
Doulatov S, Notta F, Laurenti E, Dick JE . Hematopoiesis: a human perspective. Cell Stem Cell 2012; 10: 120–136.
de Leeuw DC, Denkers F, Olthof MC, Rutten AP, Pouwels W, Schuurhuis GJ et al. Attenuation of microRNA-126 expression that drives CD34+38- stem/progenitor cells in acute myeloid leukemia leads to tumor eradication. Cancer Res 2014; 74: 2094–2105.
Cheng CJ, Bahal R, Babar IA, Pincus Z, Barrera F, Liu C et al. MicroRNA silencing for cancer therapy targeted to the tumour microenvironment. Nature 2015; 518: 107–110.
Velu CS, Chaubey A, Phelan JD, Horman SR, Wunderlich M, Guzman ML et al. Therapeutic antagonists of microRNAs deplete leukemia-initiating cell activity. J Clin Invest 2014; 124: 222–236.
This study was supported by CA135332 (GM) CA102031 (GM) and CA140158 (GM and MAC) from National Cancer Institute, National Institutes of Health. AMD was supported by a Pelotonia postdoctoral research grant and AMD and RJL were supported by a Pelotonia Idea grant.
AMD, PN and GM designed the research; CDB, MAC and GM analyzed data and provided financial and administrative support for expression and methylation analyses of AML patients; AMD, PN, XH, DN, GF, HGO, PH, JK, KM, EH, MY, RJL, LJL, BNB, HW, CMC, RG, MAC, CDB and GM performed research and/or critically reviewed and analyzed the data; AMD, PN and GM wrote the paper; and all authors critically reviewed and edited the paper.
The authors declare no conflict of interest.
Supplementary Information accompanies this paper on the Leukemia website
About this article
Cite this article
Dorrance, A., Neviani, P., Ferenchak, G. et al. Targeting leukemia stem cells in vivo with antagomiR-126 nanoparticles in acute myeloid leukemia. Leukemia 29, 2143–2153 (2015). https://doi.org/10.1038/leu.2015.139
Chemistry and Physics of Lipids (2020)
MicroRNA-126 protects against vascular injury by promoting homing and maintaining stemness of late outgrowth endothelial progenitor cells
Stem Cell Research & Therapy (2020)
European Journal of Cancer Care (2020)
Annals of Hematology (2020)
Annals of Hematology (2019)